An interventional study of Chemotherapy and surgery in Colorectal Cancer, sponsored by Vrinnevi Hospital. Terminated at 10 sites in Sweden. Per ClinicalTrials.gov, last updated 2012-05-31.
Sponsored by Vrinnevi Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 124 studies in Colorectal Neoplasms with a site in Sweden — 27 open to participants now, 38 under way, 10 of them phase 3. Colorectal Neoplasms · Sweden.
Among the 124 studies in Colorectal Neoplasms with a site in Sweden, this one is the 87th largest by enrollment of the 89 interventional ones that give a count, is one of 5 that started in 2010, is one of 25 with no phase, and was the 25th registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →27 of the 124 studies in Colorectal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:
Region Skane · Sites in Sweden
Ages 18+
GE Healthcare · Sites in Sweden, United States
Ages 18+
Suturion AB · Sites in Sweden
Ages 18+
Umeå University · Sites in Sweden
Ages 18+
GlaxoSmithKline · Sites in Sweden, United States, Canada and 6 more countries
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
124 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 28 · Phase 3 34 · Phase 4 3
First in 1998; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 215 across the 89 interventional studies, 242 across the 33 observational. Of the 73 that completed or were terminated, 19 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 124 have an industry lead sponsor. The 10 most frequent:
Vrinnevi Hospital is the lead sponsor of 6 studies on the registry; 2 are open to participants now.
Vrinnevi Hospital has 1 study filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Colorectal Neoplasms with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04486378BioNTech SEA Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | 2026-11 |
| NCT04726800Anna MartlingCirculating Tumour DNA (ctDNA) as a Prognostic and Predictive Marker in Colorectal Cancer - a Pilot Study | 2026-12 |
| NCT06333392Vestre Viken Hospital TrustTotal Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial | 2026-12 |
| NCT05755672Region SkaneOn-treatment Biomarkers in Metastatic Colorectal Cancer for Life | 2026-12 |
| NCT05838768Novartis PharmaceuticalsStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | 2027-08-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 124 studies in Colorectal Neoplasms with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
For patients with primarily generalized colorectal cancer two treatment strategies are compared to establish which strategy gives best overall survival.
The traditional strategy is to first resect the primary colorectal tumour and then treat the metastases with chemotherapy followed if possible by surgery.
The alternative strategy is to first treat the metastases with chemotherapy followed if possible by surgery and only resect the primary colorectal tumour if there is hope for cure or if symptoms develop that necessitates treatment.
Patients are randomized between the two treatment strategies mentioned above. After initial treatment the patients are categorized as palliative or treated with curative intent. Patients are followed with quality of life evaluations every 6 months. Outpatient visits, hospital care, examinations and treatment are recorded as well as complications and side effects. Survival is recorded and for those patients treated with curative intent the tumour situation 3 years after randomization is evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
First resection of the primary colorectal tumour, then treatment of metastases with chemotherapy and if possible surgery.
Procedure: Chemotherapy and surgery
First treatment of metastases with chemotherapy and if possible surgery, later resection of primary colorectal tumour if hope for cure or if symptoms develope that necessitates treatment
Procedure: Chemotherapy and surgery
Treatment not specified but in accordance with national guidelines
Overall survival
Time frame: 3 years after completion of study
3 year survival for patients treated with curative intent
Time frame: 3 years after randomization
Palliative patients not receiving chemotherapy treated with the traditional strategy
Time frame: Completion of study
Quality of life
Time frame: Every 6 months up to 3 years
Health care consumption
Time frame: Completion of study
Complications and side effects
Time frame: Completion of study
The record gives a start of Jan 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vrinnevi Hospital